Profile data is unavailable for this security.
About the company
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
- Revenue in USD (TTM)2.86m
- Net income in USD-2.20m
- Incorporated2018
- Employees1.00
- LocationCyclerion Therapeutics Inc301 Binney StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 621-7722
- Websitehttps://www.cyclerion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.20m | 8.00 | -- | 0.3288 | -- | 8.59 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Weed Inc | 0.00 | -755.25k | 4.33m | 2.00 | -- | -- | -- | -- | -0.0058 | -0.0058 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -133.78 | -117.17 | -- | -371.94 | -- | -- | -- | -- | -- | -22.55 | -- | -- | -- | -- | -1,518.25 | -- | -- | -- |
| Decoy Therapeutics Inc | 0.00 | -5.00m | 4.79m | 2.00 | -- | 0.1667 | -- | -- | -39.19 | -39.19 | 0.00 | 4.50 | 0.00 | -- | -- | 0.00 | -100.54 | -73.17 | -139.55 | -84.56 | -- | -- | -- | -987.44 | -- | -- | 0.00 | -- | -- | -- | 55.55 | -- | -- | -- |
| Bioxytran Inc | 0.00 | -2.11m | 4.82m | 2.00 | -- | -- | -- | -- | -0.0235 | -0.0235 | 0.00 | -0.0326 | 0.00 | -- | -- | -- | -1,340.44 | -1,468.56 | -- | -- | -- | -- | -- | -- | -- | -1.99 | -- | -- | -- | -- | 47.08 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 2.86m | -2.20m | 4.87m | 1.00 | -- | 0.4804 | -- | 1.70 | -0.7587 | -0.7587 | 1.00 | 2.58 | 0.2957 | -- | 39.65 | 2,855,000.00 | -22.77 | -53.70 | -24.80 | -63.57 | -- | -- | -77.02 | -1,913.83 | -- | -- | 0.00 | -- | -- | -15.00 | 75.72 | -- | -- | -- |
| Processa Pharmaceuticals Inc | 0.00 | -12.93m | 4.94m | 10.00 | -- | 0.7902 | -- | -- | -35.00 | -35.00 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -206.50 | -104.23 | -270.68 | -112.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -9.25m | 4.94m | 11.00 | -- | 0.708 | -- | -- | -25.21 | -25.21 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -125.80 | -- | -221.96 | -- | -- | -- | -- | -- | -- | -84.50 | 0.1808 | -- | -- | -- | -223.39 | -- | -- | -- |
| MetaVia Inc | 0.00 | -16.22m | 4.94m | 9.00 | -- | 0.5355 | -- | -- | -13.88 | -13.88 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -87.87 | -99.54 | -167.49 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 4.99m | 2.00 | -- | 0.8502 | -- | 1.75 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| VivoSim Labs Inc | 142.00k | -1.23m | 5.01m | 5.00 | 1.80 | 1.13 | -- | 35.26 | 1.07 | 1.07 | 0.0608 | 1.70 | 0.0263 | -- | 4.81 | 10,923.08 | -22.71 | -51.63 | -45.51 | -56.47 | 100.00 | -- | -864.08 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -9.17m | 5.04m | 4.00 | -- | 0.9801 | -- | -- | -8.54 | -8.54 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -151.72 | -158.12 | -291.07 | -208.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.26 | -- | -- | -- |
| Bio Green Med Solution Inc | 81.00k | -6.97m | 5.05m | 12.00 | -- | 0.5079 | -- | 62.31 | -80.13 | -80.13 | 0.0775 | 2.03 | 0.012 | -- | 0.0821 | -- | -80.35 | -65.34 | -175.85 | -83.85 | 20.99 | -- | -6,714.82 | -17,774.73 | 5.07 | -241.39 | 0.00 | -- | -89.76 | -- | 50.73 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.47m | -2.30m | 5.20m | 30.00 | -- | 0.5799 | -- | 0.5494 | -1.28 | -1.28 | 5.27 | 3.79 | 1.02 | 6.73 | 6.42 | -- | -24.68 | -6.00 | -27.80 | -7.75 | 14.77 | 14.31 | -24.27 | -4.98 | 6.81 | -1,354.05 | 0.00 | -- | -2.66 | 137.09 | 39.20 | -- | 77.67 | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 5.24m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.38m | 28.00 | -- | 0.7487 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Aspire Biopharma Holdings Inc | 1.94k | -28.70m | 5.50m | -- | -- | -- | -- | 2,836.72 | -65.96 | -65.96 | 0.0022 | -9.26 | 0.0004 | -- | -- | -- | -633.21 | -- | -- | -- | 45.36 | -- | -1,479,598.00 | -- | 0.1708 | -6.20 | -- | -- | -- | -- | -380.85 | -- | -- | -- |
Data as of Feb 18 2026. Currency figures normalised to Cyclerion Therapeutics Inc's reporting currency: US Dollar USD
3.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2025 | 43.30k | 1.10% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 16.80k | 0.43% |
| BG Fund Management Luxembourg SAas of 30 Jun 2025 | 16.43k | 0.42% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 16.14k | 0.41% |
| Two Sigma Investments LPas of 30 Sep 2025 | 13.29k | 0.34% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 8.20k | 0.21% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 7.35k | 0.19% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 4.74k | 0.12% |
| Tower Research Capital LLCas of 30 Sep 2025 | 2.33k | 0.06% |
| UBS Securities LLCas of 31 Dec 2025 | 376.00 | 0.01% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
